Copyright
©The Author(s) 2016.
World J Hepatol. Feb 28, 2016; 8(6): 331-339
Published online Feb 28, 2016. doi: 10.4254/wjh.v8.i6.331
Published online Feb 28, 2016. doi: 10.4254/wjh.v8.i6.331
Table 1 Patient demographics n (%)
| Boceprevir plus PR (n = 159) | PR (n = 78) | |
| Sex | ||
| Male | 94 (59.1) | 45 (57.7) |
| Female | 65 (40.9) | 33 (42.3) |
| Age (yr), mean (SD) | 38.6 (9.8) | 38.1 (10.0) |
| Race | ||
| White | 158 (99.4) | 77 (98.7) |
| Asian | 1 (0.6) | 1 (1.3) |
| Ethnicity | ||
| Not Hispanic or Latino | 159 (100) | 78 (100) |
| Weight (kg), mean (SD) | 78.1 (16.6) | 78.5 (16.8) |
| BMI (kg/m2), mean (SD) | 25.9 (4.2) | 26.0 (4.4) |
| Previous treatment | ||
| Naive | 97 (61.0) | 48 (61.5) |
| Experienced | 62 (39.0) | 30 (38.5) |
| IL28B genotype | ||
| CC allele | 22 (13.8) | 11 (14.1) |
| Non-CC allele | 137 (86.2) | 67 (85.9) |
| HCV genotype | ||
| GT1a | 4 (2.5) | 0 (0) |
| GT1b | 155 (97.5) | 78 (100) |
| Baseline HCV RNA | ||
| ≤ 800000 IU/mL | 89 (56.0) | 53 (67.9) |
| > 800000 IU/mL | 70 (44.0) | 25 (32.1) |
| Hemoglobin (g/dL), mean (SD) | 15.0 (1.5) | 14.9 (1.5) |
| Liver histology | ||
| Cirrhosis | 7 (4.4) | 2 (2.6) |
| No cirrhosis | 152 (95.6) | 76 (97.4) |
- Citation: Isakov V, Nikitin I, Chulanov V, Ogurtsov P, Lukyanova E, Long J, Wahl J, Helmond FA, The P08160 Trial Investigators. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World J Hepatol 2016; 8(6): 331-339
- URL: https://www.wjgnet.com/1948-5182/full/v8/i6/331.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i6.331